JP2021518390A5 - - Google Patents

Info

Publication number
JP2021518390A5
JP2021518390A5 JP2020550644A JP2020550644A JP2021518390A5 JP 2021518390 A5 JP2021518390 A5 JP 2021518390A5 JP 2020550644 A JP2020550644 A JP 2020550644A JP 2020550644 A JP2020550644 A JP 2020550644A JP 2021518390 A5 JP2021518390 A5 JP 2021518390A5
Authority
JP
Japan
Prior art keywords
variable region
chain variable
region sequence
seq
heavy chain
Prior art date
Application number
JP2020550644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518390A (ja
JP7514765B2 (ja
JPWO2019182867A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022295 external-priority patent/WO2019182867A1/en
Publication of JP2021518390A publication Critical patent/JP2021518390A/ja
Publication of JPWO2019182867A5 publication Critical patent/JPWO2019182867A5/ja
Publication of JP2021518390A5 publication Critical patent/JP2021518390A5/ja
Priority to JP2023095570A priority Critical patent/JP7713995B2/ja
Priority to JP2024105891A priority patent/JP7783350B2/ja
Application granted granted Critical
Publication of JP7514765B2 publication Critical patent/JP7514765B2/ja
Priority to JP2025205320A priority patent/JP2026035716A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550644A 2018-03-23 2019-03-14 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法 Active JP7514765B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023095570A JP7713995B2 (ja) 2018-03-23 2023-06-09 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2024105891A JP7783350B2 (ja) 2018-03-23 2024-07-01 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2025205320A JP2026035716A (ja) 2018-03-23 2025-11-27 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647407P 2018-03-23 2018-03-23
US62/647,407 2018-03-23
US201862755408P 2018-11-02 2018-11-02
US62/755,408 2018-11-02
PCT/US2019/022295 WO2019182867A1 (en) 2018-03-23 2019-03-14 Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023095570A Division JP7713995B2 (ja) 2018-03-23 2023-06-09 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2024105891A Division JP7783350B2 (ja) 2018-03-23 2024-07-01 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2021518390A JP2021518390A (ja) 2021-08-02
JPWO2019182867A5 JPWO2019182867A5 (https=) 2022-03-22
JP2021518390A5 true JP2021518390A5 (https=) 2022-03-22
JP7514765B2 JP7514765B2 (ja) 2024-07-11

Family

ID=67987457

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020550644A Active JP7514765B2 (ja) 2018-03-23 2019-03-14 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2023095570A Active JP7713995B2 (ja) 2018-03-23 2023-06-09 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2024105891A Active JP7783350B2 (ja) 2018-03-23 2024-07-01 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2025205320A Pending JP2026035716A (ja) 2018-03-23 2025-11-27 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023095570A Active JP7713995B2 (ja) 2018-03-23 2023-06-09 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2024105891A Active JP7783350B2 (ja) 2018-03-23 2024-07-01 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2025205320A Pending JP2026035716A (ja) 2018-03-23 2025-11-27 ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法

Country Status (12)

Country Link
US (2) US12134648B2 (https=)
EP (1) EP3768723A4 (https=)
JP (4) JP7514765B2 (https=)
KR (1) KR20200135785A (https=)
CN (3) CN117586412A (https=)
AU (2) AU2019239568B2 (https=)
BR (1) BR112020019042A2 (https=)
CA (1) CA3092687A1 (https=)
IL (1) IL277211A (https=)
MX (1) MX2020009902A (https=)
SG (1) SG11202009258RA (https=)
WO (1) WO2019182867A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075097A1 (en) 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
CN119101158A (zh) 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP3768726B1 (en) * 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
IL301306A (en) * 2020-09-16 2023-05-01 Harvard College Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
TW202405011A (zh) * 2022-04-01 2024-02-01 美國德州系統大學評議委員會 針對人類pd-l1及pd-l2之雙重特異性抗體及其使用方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20040131613A1 (en) * 2003-01-08 2004-07-08 Watkins Jeffry D. TNF-alpha binding molecules
JP4999158B2 (ja) 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌(bachillusanthracis)の感染防御抗原に対するヒトモノクローナル抗体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20090304721A1 (en) 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TW200927761A (en) 2007-09-26 2009-07-01 U3 Pharma Ag Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
US9044457B2 (en) 2010-06-16 2015-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-DR4 agonist antibodies
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
JP6403166B2 (ja) * 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 単一抗原抗pd−l1およびpd−l2二重結合抗体およびその使用方法
KR20220062143A (ko) 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
AU2016229201B2 (en) 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016160792A1 (en) 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
CA2995502A1 (en) 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
KR20240133761A (ko) 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
EP3390454B1 (en) 2015-12-17 2026-02-04 University of Maryland, Baltimore County A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
KR20180130541A (ko) 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
WO2017200796A1 (en) 2016-05-17 2017-11-23 Albert Einstein College Of Medicine, Inc. Engineered pd-1 variants
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2019075097A1 (en) 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN119101158A (zh) 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor

Similar Documents

Publication Publication Date Title
JP2021518390A5 (https=)
CN113748133B (zh) 肿瘤治疗剂及其应用
JP2021518415A5 (https=)
CN114805575B (zh) 人源化抗cd73抗体
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
CN111454357B (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
US20210230269A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
JP2021514664A5 (https=)
CN108084265B (zh) 特异性结合人的5t4抗原的全人源单域抗体及其应用
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2021528047A5 (https=)
JP2018520334A5 (https=)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
CN116848135A (zh) 新颖的抗gremlin1抗体
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
CN107001452A (zh) 用于治疗癌症的抗ck8抗体
JPWO2019182867A5 (https=)
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
CN112805297B (zh) 抗人类pd-l1抗体及其用途
CN115989243A (zh) 一种抗pd-l1/vegf融合蛋白
JPWO2019182888A5 (https=)
JP7808831B2 (ja) 抗cd26抗体とその応用
JPWO2023129928A5 (https=)
KR20220092666A (ko) 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
EP4121106A1 (en) New anti-vegfc antibodies and uses thereof